Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
ICON PUBLIC LIMITED COMPANY Funds and ETFs ICON Public Limited Company
Equities
ICLR
IE0005711209
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 269.35 USD | +0.90% | -0.93% | +38.66% | |
| Nov. 30 | Deutsche Bank Raises ICON Price Target to $320 From $295, Maintains Buy Rating | MT |
| Nov. 30 | Data keeps fueling the momentum |  |
ETFs positioned on ICON Public Limited Company
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.74% | 3 M€ | -15.62% | ||
| 4.50% | 83 M€ | +26.39% | ||
| 4.33% | 396 M€ | -3.81% | ||
| 4.10% | 4 M€ | +15.01% | - | |
| 3.68% | 2 M€ | -.--% | ||
| 3.43% | 7 M€ | +19.03% | - | |
| 2.57% | 0 M€ | -.--% | - | |
| 2.54% | 70 M€ | +7.41% | ||
| 2.54% | 3 M€ | +10.03% | ||
| 2.22% | 7 M€ | +1.78% | - | |
| 2.14% | 309 M€ | +9.04% | - | |
| 1.87% | 57 M€ | 0.00% | - | |
| 1.72% | 6 M€ | 0.00% | ||
| 1.72% | 164 M€ | +1.38% | ||
| 1.61% | 114 M€ | +9.91% | - | |
| 1.59% | 31 M€ | -.--% | ||
| 1.58% | 0 M€ | -.--% | - | |
| 1.58% | 566 M€ | +6.94% | ||
| 1.58% | 0 M€ | 0.00% | - | |
| 1.28% | 6 M€ | 0.00% | - | |
| 1.26% | 1,415 M€ | +20.33% | ||
| 1.20% | 4 M€ | +4.46% | - | |
| 1.12% | 75 M€ | +4.00% | - | |
| 1.03% | 3 M€ | +15.90% | - | |
| 0.91% | 4 M€ | +7.38% | ||
| 0.91% | 2 M€ | +3.55% | ||
| 0.85% | 74 M€ | +10.73% | ||
| 0.79% | 1,179 M€ | +15.59% | - | |
| 0.71% | 9 M€ | +18.91% | - | |
| 0.70% | 24 M€ | +25.10% | - | |
| 0.70% | 14 M€ | +11.80% | ||
| 0.57% | 6 M€ | +11.71% | - | |
| 0.53% | 20 M€ | +13.89% | ||
| 0.53% | 186 M€ | +7.71% | - | |
| 0.50% | 25 M€ | +15.46% | ||
| 0.48% | 37 M€ | -1.98% | - | |
| 0.48% | 1 M€ | -.--% | - | |
| 0.42% | 49 M€ | +16.41% | ||
| 0.42% | 41 M€ | +12.59% | - | |
| 0.42% | 95 M€ | +8.81% | - |
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors. Its sectors include Biosimilars, Biotech, Government and public health solutions, medical devices, pharmaceuticals and the IVDR journey.
Calendar
2024-02-20
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
269.35USD
Average target price
285.14USD
Spread / Average Target
+5.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +38.66% | 22 175 M $ | |
| +65.53% | 40 132 M $ | |
| +5.87% | 39 586 M $ | |
| -55.56% | 30 438 M $ | |
| -26.11% | 28 571 M $ | |
| -27.87% | 21 511 M $ | |
| +1.62% | 17 412 M $ | |
| -13.43% | 11 313 M $ | |
| -7.44% | 10 346 M $ | |
| -22.08% | 10 212 M $ |
- Stock
- Equities
- Stock ICON Public Limited Company - Nasdaq
- Funds and ETFs ICON Public Limited Company
